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TO THE EDITOR
In the majority of cases, Merkel cell
carcinoma (MCC) harbors Merkel cell
polyomavirus (MCV) DNA, which—at
least in the tested cases—is clonally
integrated at random sites of the host
genome and carries characteristic mu-
tations (Feng et al., 2008; Shuda et al.,
2008; Sastre-Garau et al., 2009). The
latter notion together with our recent
reports demonstrating that the expres-
sion of the MCV-derived T antigens
(TAs) is essential for growth of MCC cell
lines in vitro, and in vivo has estab-
lished MCV as a causative factor in the
oncogenesis of MCC (Houben et al.,
2010, 2011). The immunological char-
acteristics of MCC as discussed in
recent reports corroborates with this
hypothesis (Paulson et al., 2011; Touze
et al., 2011). For example, Touze et al.
(2011) demonstrated that high titers of
antibodies against the viral capsid
protein VP1 are more frequently de-
tected in MCC patients—although VP1
seems not to be expressed in the
tumors—than in a control cohort further
supporting MCV infection as a causa-
tive factor in most MCC cases. More-
over, Touze et al. (2011) confirm
several previous reports that in a sub-
stantial fraction of the MCV-positive
MCCs the virus is present with less than
one copy per cell. For these tumors a
role of MCV in their etiology is unclear.
In this regard, published data on the
impact of MCV presence or viral load
on the clinical characteristics of MCC is
conflicting. In two recent reports, a
worse prognosis for patients with MCV-
negative tumors or tumors with low
viral copy per cell numbers and lack of
large T-antigen (LTA) expression have
been reported (Sihto et al., 2009; Bhatia
et al., 2010). In others, as well as in our
own series, no statistical significant
survival differences between patients
with MCV-positive or -negative tumors
were evident (Handschel et al., 2010;
Schrama et al., 2011). In their recent
publication, Touze et al. (2011) re-
ported a better progression-free survival
for patients with high MCV VP1 anti-
body titers. Thus, based on their own
findings and the reports in the literature,
they suggest a model with two sub-
groups of MCC: one less aggressive
with clear MCV etiology, as demon-
strated by high viral load, LTA expres-
sion, and high titers of MCV antibodies;
and a second more aggressive type of
MCC with a different etiology, as
indicated by low viral load, lack of
LTA expression, and MCV antibody
titers similar to those observed in the
general population. However, although
high MCV antibody titers (410,000)
are observed in only 7.3% of the
controls, 61.5%, 65%, and 61.1% of
the MCC patients with a virus copy per
cell of o1, 1–9, and 49, respectively,
demonstrated such a high anti-VP1
antibody titers (Touze et al., 2011)
arguing against a correlation of viral
load and anti-VP1 antibody titer. In
contrast, however, VP1 antibody titers
in non-MCC patients seem to be correl-
ative to viral presence in the skin (Faust
et al., 2011). Consequently, when high-
er MCV antibodies levels in MCC
patients are regarded as an indication
for MCV etiology, these data would
support the idea that MCV has also
been a causal factor for many MCCs
even if the MCV genome is not detected
in every cell at the time of analysis. It
seems conceivable that viral infection
initially induces transformation, but
that some transformed cells may be-
come independent of MCV. Indeed,
adenovirus transformed hamster cells
can retain their oncogenic phenotype
even though the previously integrated
Abbreviations: LTA, large T antigen; MCC, Merkel cell carcinoma; MCV, Merkel cell polyomavirus;
shRNA, small hairpin RNA; TA, T antigen
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viral DNA is lost (Pfeffer et al., 1999).
Overcoming the addiction to the viral
oncoproteins is a prerequisite for such a
process. Such a loss of oncogene
addiction has been observed in animal
models: in transgenic mice, the induc-
ible expression of SV40 TAs in the
submandibular gland resulted in a
severe hyperplasia; silencing of the TA
expression within the first 4 months
resulted in restitution of the normal
state, whereas silencing at later time
points was not associated with a regres-
sion anymore (Ewald et al., 1996).
Importantly, a similar phenomenon
might exist in MCC. We recently
demonstrated that MCV-positive MCC
cell lines strictly depend on the expres-
sion of the MCV TAs as TA knockdown
leads to growth repression, whereas
MCV-negative cell lines were not af-
fected by the TA small hairpin RNA
(shRNA; Houben et al., 2010). Notably,
however, we also established one
MCV-positive cell line (LoKe), which
upon TA knockdown—in contrast to
seven other MCV-positive cell lines
tested—does not display any growth
inhibition (Figure 1). LoKe cells were
derived from a 65-year-old male patient
with histologically confirmed MCC.
The LoKe MCV LTA-coding sequence
demonstrates the MCC characteristic
premature stop codon mutation delet-
ing the helicase domain. The truncated
LTA consists of 254 amino acids in-
cluding the Retinoblastoma protein
binding-motif (data not shown; Houben
et al., 2011). The integration of the
viral genome in chromosome 2 of
the tumor cells was detected by apply-
ing detection of integrated ‘‘polyoma’’
sequences technology (Sastre-Garau
et al., 2009; data not shown). Quantita-
tive PCR revealed an MCV virus load of
more than one virus genome per cell and
immunocytochemistry demonstrated LTA
expression in the vast majority of cells. In
addition, serum of the respective patient
contained high antibody titers against
VP1 (Figure 2) and the TAs (data not
shown). All this data together imply the
involvement of MCV in oncogenic trans-
formation of the LoKe cells. Although we
cannot exclude that the TA knockdown
achieved by our shRNA is simply not
efficient enough in LoKe cells, we think
that it is more likely that these cells have
acquired additional aberrations enabling
growth even in the absence of T-antigen
expression. Thus, in some MCC cases,
MCV may only be necessary for tumor
initiation, whereas additional mutations
during tumor progression render T-anti-
gen expression dispensable for them.
This might lead on one hand to the loss
of MCV within these tumors and on the
other to a different biological behavior
including a more aggressive phenotype.
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Figure 1. T-antigen (TA) knockdown induces growth repression in the Merkel cell polyomavirus (MCV)-positive cell line MKL-1, but does not impair growth of
the MCV-positive Merkel cell carcinoma cell line LoKe. The ratio of TA small hairpin RNA (shRNA)-infected cells versus uninfected cells was measured over
time (for details see Houben et al. (2010)). Displayed are mean values (±SD) of 16 and 6 independent experiments for MKL-1 and LoKe, respectively.
Immunoblotting demonstrates large T-antigen (LTA) knockdown in TA shRNA-infected cells. Flow cytometry (the shRNA vector also encodes green fluorescence
protein) demonstrated that the lysates were derived from cell populations with TA shRNA infection rates of 81% and 74% for MKL-1 or LoKe, respectively.
Scr, scrambled.
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Figure 2. High level of Merkel cell polyomavirus (MCV)-VP1 antibodies in serum of the patient from
which the LoKe cell line was derived. Serum samples of melanoma and MCC patients were tested for the
presence of VP1-neutralizing antibodies in a MCV neutralization assay (Pastrana et al., 2009). The EC50
values for neutralization of MCV-like particles by antibodies against VP1 were calculated for every
sample. Serum of a VP1-immunized rabbit was included in every individual measurement and was used
for normalization. A detailed protocol of the assay and data analysis can be found here:
http://home.ccr.cancer.gov/Lco/MCVNeutralizationAssay.htm.
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